Neutralizing the neurotoxic effects of exogenous and endogenous tPA. - Wikidata - awgldk - TriplyDB

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

http://www.wikidata.org/entity/Q48435483

about

Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice Key role of tissue plasminogen activator in neurovascular coupling Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans Delayed postconditioning protects against focal ischemic brain injury in rats.Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion Emerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic Agents Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity Insulin and glucagon share the same mechanism of neuroprotection in diabetic rats: role of glutamate Blood-brain barrier permeability and tPA-mediated neurotoxicity.Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats tPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury.Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.Endothelin and the neurovascular unit in pediatric traumatic brain injury.Dopamine prevents impairment of autoregulation after traumatic brain injury in the newborn pig through inhibition of Up-regulation of endothelin-1 and extracellular signal-regulated kinase mitogen-activated protein kinase.Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13 Neuroprotection and stroke: time for a compromise.Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.Novel actions of tissue-type plasminogen activator in chronic kidney disease.Neurodegeneration induced by PVC-211 murine leukemia virus is associated with increased levels of vascular endothelial growth factor and macrophage inflammatory protein 1 alpha and is inhibited by blocking activation of microglia tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1.Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.Emerging neuroprotective drugs for the treatment of acute ischaemic stroke.Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms.tPA Modulation of the Blood-Brain Barrier: A Unifying Explanation for the Pleiotropic Effects of tPA in the CNS.Longitudinal assessment of imatinib's effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI.Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1.Tissue plasminogen activator induced delayed edema in experimental porcine intracranial hemorrhage: reduction with plasminogen activator inhibitor-1 administration.Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity.Fibrinolysis: from blood to the brain.Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.

P2860

Q27320059-C21936BB-8DA2-4ABA-8604-6827EBE439BA Q28512912-1180A967-D10A-4260-8A7F-79710DE8DE17 Q28552445-B21B0DEF-1146-4BAA-BB5C-F6DE125101CA Q30528502-58FAF8C8-3FBF-46A6-B660-A76A03D3427D Q33391388-B8C3C993-B8A5-4EB7-8810-251F9DD78C6F Q33600876-AF7BD63B-1614-4234-8028-4726A29B61A9 Q33767438-6AEB5EDA-1046-4E2D-AE93-B26A40A3FF39 Q33783563-3B40843C-EB35-48DC-B6B2-94558C302426 Q34006140-E4961D3C-CA94-4579-BA64-1169EADC23C1 Q34018715-B3D7773C-320E-4933-936D-6E4B432F98AC Q34171180-523BBAA6-0A9C-42CB-A088-914B2EDF88E2 Q34363696-CFFE62B0-2AE8-482D-9208-F10382932892 Q34504984-7A5EC813-69E2-402D-91BD-ECC470F24033 Q35217410-E170B683-3226-48EC-8E84-82797B8C5B63 Q35580943-BFF2FA95-520C-4CAC-A439-96E6B99B03FC Q35675445-AF19DDF6-8058-4ED0-A08D-071B9F90C422 Q35989919-335172A2-C09F-448E-B122-1CA764861B89 Q36307742-9493D8DB-4E2C-44AD-AD78-327DEC469162 Q36473166-23660201-E261-4E23-9852-E5F337693334 Q36512703-3C0ACD0C-2F76-4A40-9762-CAE574D67CF5 Q36534737-CED302DF-BBC3-4E8E-9E73-A77411A4688C Q36595057-E55987E3-3BAB-4CDE-8D8F-973BCFBD9737 Q36903087-C151BE74-DE2C-420A-9404-7A1DA7A91A3F Q36922560-9BC56C2C-14D0-4BD1-8DF8-F8333C01CE39 Q36925788-AB1B3723-7844-4B17-9FDE-9BF7F675C11B Q37115034-4B64CF7D-8551-4CFE-AE71-119C3D010A83 Q37192113-E6432DB1-E0F6-4B76-8EC5-9B49B7F9B548 Q37272721-6098567D-C210-456F-93B6-E8E371D2B355 Q37285884-534C4CD5-5251-490F-B830-D6B61EB77225 Q37397703-B10071C1-9278-440B-8567-E18E20C8474F Q38100263-F7B2FDB9-CF74-4B27-9A8B-84F47828000D Q38198639-39A73265-6891-4B81-8832-F5C7513D9C26 Q38965982-D602624B-7D47-438C-AA30-B005C6FA2AB8 Q39141643-9C112DE8-C3CE-4BE8-89FD-5B688C989713 Q41466753-91DB4148-28EA-4E0F-9AB5-ED84B8EF729D Q41962747-AD643B85-12CA-4E4D-AB6E-D0C1A4AA0A55 Q46008327-D29C9EC9-D697-4105-B0C8-25A3F6262F9F Q46268137-577E5A41-A6B4-40AD-9371-050D96BF2056 Q48106697-AF769966-98AC-404D-ABFE-0371D6C02CA7 Q48914597-F16EB831-892B-4743-B6ED-1FA41987207A

P2860

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

http://www.wikidata.org/entity/Q48435483

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

@en

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

@nl

type

label

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

@en

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

@nl

prefLabel

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

@en

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

@nl

P1433

Q48435483-0C538817-B394-4E8E-A889-F38017A924F0

P1476

Q48435483-399C496C-E981-4982-9350-46EA58E56892

P2093

Q48435483-0D8D5EFD-D302-4B65-8178-4753F3F5B156

Q48435483-829FDF08-064D-4DF3-A5EB-1D5AA018830F

Q48435483-94289F7F-BDBE-4B9C-9764-1A19F433D75A

Q48435483-A4D89177-3198-4EA5-A8BE-F2A1FDAD06E4

Q48435483-F09F9D62-B48B-461C-81C0-9B2AE662DDC8

Q48435483-F1C26D0A-54D6-49E3-9511-1193F838542D

Q48435483-F907C615-70FC-44A3-8AFE-171F83F7085B

P2860

Q48435483-196B8395-03B5-4101-941F-D6A487A0766A

Q48435483-23344F23-476B-4D1A-AD9F-094C5C5FF915

Q48435483-2C9C8F15-B3D2-4BA0-8CF5-BB06956BCF23

Q48435483-39A4564B-A01D-40E0-825C-8339E1393FF7

Q48435483-4332529B-62F2-41F6-A3F1-CD7F258E4143

Q48435483-482B5AD6-6599-4A0D-91FD-CB87EA7A0485

Q48435483-50B377E3-47B1-4588-9A32-202D9551A749

Q48435483-56485CF3-78E2-438C-A11E-730BD52E85E0

Q48435483-592D7715-DE88-48A7-A991-0F701C33C61F

Q48435483-93DECB14-468A-409E-A898-0EEE0E8A4AF6

P2888

Q48435483-AEC98815-8F17-4B60-9FE2-2CBBE88285EE

P304

Q48435483-16DA5361-412E-4B5B-848E-F6A8280A2BD9

P31

Q48435483-CBCF7D06-BBA4-4078-BEFA-A3B98D9145F8

P356

Q48435483-BA88BC97-CDB2-4D88-9EF7-91396ABD2AE3

P407

Q48435483-26327274-378C-4043-9DA9-85CE3D2E0964

P433

Q48435483-E90F51EA-7D3F-499A-A1D1-C78A1C5C3178

P478

Q48435483-01A939DA-1644-455A-B7F1-B00C57FF42D9

P577

Q48435483-836F63DE-BF95-402B-98ED-D7AF5A86E3C5

P5875

Q48435483-F714B252-76BC-499F-8A3E-097C26BF8BB3

P698

Q48435483-69479690-24AD-4D0D-A777-D0BA41077FC6

P921

Q48435483-F59C396E-A892-4028-B4D9-DAB9C8FD56CD

P356

P1433

Nature Neuroscience

P1476

Neutralizing the neurotoxic effects of exogenous and endogenous tPA.

@en

P2093

Abd Al-Roof Higazi

http://www.w3.org/2001/XMLSchema#string

Douglas B Cines

http://www.w3.org/2001/XMLSchema#string

Douglas H Smith

http://www.w3.org/2001/XMLSchema#string

Saed Akkawi

http://www.w3.org/2001/XMLSchema#string

Taher Nassar

http://www.w3.org/2001/XMLSchema#string

William M Armstead

http://www.w3.org/2001/XMLSchema#string

Xiao-Han Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Mouse model of microembolic stroke and reperfusion.

Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1

Thrombolytic stroke therapy: past, present, and future.

Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents.

Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment.

Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin

Maturation of circulatory system in three mammalian models of human development.

Animate models of human head injury.

Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.

Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.

P2888

P304

1150-1155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NN1757

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232799550

http://www.w3.org/2001/XMLSchema#string

P698

16936723

http://www.w3.org/2001/XMLSchema#string

P921